{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:11:43Z","timestamp":1790881903656,"version":"4.1.0"},"reference-count":44,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4,1]]},"DOI":"10.1210\/jc.2009-1703","type":"journal-article","created":{"date-parts":[[2010,2,17]],"date-time":"2010-02-17T21:34:35Z","timestamp":1266442475000},"page":"1838-1845","source":"Crossref","is-referenced-by-count":226,"title":["Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis"],"prefix":"10.1210","volume":"95","author":[{"given":"Joel S.","family":"Finkelstein","sequence":"first","affiliation":[{"name":"Department of Medicine, Endocrine Unit (J.S.F., J.J.W., R.M.N.), Massachusetts General Hospital, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Wyland","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrine Unit (J.S.F., J.J.W., R.M.N.), Massachusetts General Hospital, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lee","sequence":"additional","affiliation":[{"name":"Biostatistics Center (H.L.), Massachusetts General Hospital, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Neer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrine Unit (J.S.F., J.J.W., R.M.N.), Massachusetts General Hospital, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113450724400_R1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041113450724400_R2","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113450724400_R3","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jama.280.12.1067","article-title":"Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized, controlled trial","volume":"280","author":"Finkelstein","year":"1998","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113450724400_R4","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199412153312404","article-title":"Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency","volume":"331","author":"Finkelstein","year":"1994","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113450724400_R5","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113450724400_R6","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113450724400_R7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1073\/pnas.96.1.133","article-title":"Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro","volume":"96","author":"Fisher","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2019041113450724400_R8","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113450724400_R9","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/jc.2006-0190","article-title":"Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men","volume":"91","author":"Finkelstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113450724400_R10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113450724400_R11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1359\/jbmr.1997.12.4.652","article-title":"Total body bone mineral density in young children: influence of head bone mineral density","volume":"12","author":"Taylor","year":"1997","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113450724400_R12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00004424-198505000-00014","article-title":"Quantitative computed tomography for spinal density measurement. Factors affecting precision","volume":"20","author":"Rosenthal","year":"1985","journal-title":"Invest Radiol"},{"key":"key\n\t\t\t\t2019041113450724400_R13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041113450724400_R14","first-page":"3069","article-title":"Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers","volume":"85","author":"Kurland","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113450724400_R15","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041113450724400_R16","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1210\/jc.2008-2630","article-title":"Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis","volume":"94","author":"Leder","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113450724400_R17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0002-9343(97)00137-X","article-title":"Biochemical markers in the assessment of bone disease","volume":"103","author":"Bikle","year":"1997","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041113450724400_R18","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1359\/jbmr.080231","article-title":"Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis","volume":"23","author":"Chavassieux","year":"2008","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113450724400_R19","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1210\/en.2002-220221","article-title":"Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos","volume":"143","author":"Demiralp","year":"2002","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019041113450724400_R20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/8756-3282(95)00113-R","article-title":"The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate\u2014is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?","volume":"16","author":"Delmas","year":"1995","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041113450724400_R21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00223-008-9104-y","article-title":"Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro","volume":"82","author":"Idris","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"key\n\t\t\t\t2019041113450724400_R22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/jbmr.5650040321","article-title":"Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo","volume":"4","author":"Hock","year":"1989","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113450724400_R23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jbmr.5650070110","article-title":"Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone","volume":"7","author":"Hock","year":"1992","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113450724400_R24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/8756-3282(94)00036-Y","article-title":"Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats","volume":"16","author":"Baumann","year":"1995","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041113450724400_R25","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1210\/endo.132.2.8425497","article-title":"Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats","volume":"132","author":"Wronski","year":"1993","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019041113450724400_R26","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1210\/en.2002-221061","article-title":"New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats","volume":"144","author":"Ma","year":"2003","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019041113450724400_R27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1172\/JCI113885","article-title":"Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures","volume":"83","author":"Canalis","year":"1989","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019041113450724400_R28","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1210\/endo-124-3-1247","article-title":"Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast enriched cultures from fetal rat bone","volume":"124","author":"McCarthy","year":"1989","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019041113450724400_R29","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1359\/jbmr.2002.17.9.1570","article-title":"Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone","volume":"17","author":"Bikle","year":"2002","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113450724400_R30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.bbrc.2006.01.044","article-title":"Impaired bone anabolic response to parathyroid hormone in Fgf2\u2212\/\u2212 and Fgf2+\/\u2212 mice","volume":"341","author":"Hurley","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"key\n\t\t\t\t2019041113450724400_R31","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1210\/en.2004-1511","article-title":"Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice","volume":"146","author":"Yamaguchi","year":"2005","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019041113450724400_R32","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0006-291X(89)92795-2","article-title":"Activation of the bone derived latent TGF-\u03b2 complex by isolated osteoclasts","volume":"158","author":"Oreffo","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"key\n\t\t\t\t2019041113450724400_R33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","article-title":"Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal","volume":"16","author":"Cosman","year":"2001","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113450724400_R34","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041113450724400_R35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1359\/JBMR.051020","article-title":"Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy","volume":"21","author":"Ste-Marie","year":"2006","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113450724400_R36","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113450724400_R37","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113450724400_R38","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113450724400_R39","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113450724400_R40","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","article-title":"Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate","volume":"93","author":"Miller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113450724400_R41","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113450724400_R42","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/jbmr.5650010411","article-title":"Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D","volume":"1","author":"Slovik","year":"1986","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113450724400_R43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113450724400_R44","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.1998.13.6.1051","article-title":"Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women","volume":"13","author":"Cosman","year":"1998","journal-title":"J Bone Miner Res"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/95\/4\/1838\/10780725\/jcem1838.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T21:15:12Z","timestamp":1558818912000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/95\/4\/1838\/2597220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,1]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2009-1703","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,1]]}}}